Symbravo (Meloxicam and Rizatriptan) for Migraine

Overview

Symbravo is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults. It should only be used when a clear diagnosis of migraine has been made. Symbravo is not intended for the prevention of migraine or for the treatment of cluster headaches. Symbravo is also known by its drug name, meloxicam and rizatriptan.

Symbravo combines two types of drugs: meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and rizatriptan, a serotonin (5-HT) 1B/1D receptor agonist (also known as a triptan). Meloxicam helps reduce pain and inflammation, while rizatriptan works by narrowing blood vessels in the brain and reducing substances that can trigger migraine symptoms.

How do I take it?

Prescribing information states that Symbravo is taken by mouth as a tablet. The recommended dose is one tablet as needed for a migraine attack. The drug should be taken exactly as prescribed by a health care provider.

Side effects

Common side effects of Symbravo include dizziness and somnolence (drowsiness).

Rare but serious side effects may include cardiovascular thrombotic events such as myocardial infarction (heart attack) and stroke, gastrointestinal bleeding or ulcers, anaphylactic reactions (severe allergic responses), arrhythmias (irregular heartbeats), cerebral hemorrhage (brain bleeding), hepatotoxicity (liver damage), serious skin reactions, and renal toxicity (kidney damage). Other serious risks include hypertension (high blood pressure), heart failure, hyperkalemia (high potassium levels), serotonin syndrome (a potentially life-threatening condition), and worsening of asthma in people sensitive to aspirin. There is also a risk of fetal harm if used during pregnancy, and possible reversible infertility in women, according to the prescribing information.

For more information about this treatment, visit:
Symbravo (Meloxicam and Rizatriptan) Tablets, for Oral Use — Axsome Therapeutics